• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌的住院和医疗护理天数。

Hospital and medical care days in pancreatic cancer.

机构信息

Department of Surgery, The University of Texas Medical Branch, Galveston, TX, USA.

出版信息

Ann Surg Oncol. 2012 Aug;19(8):2435-42. doi: 10.1245/s10434-012-2326-2. Epub 2012 Mar 27.

DOI:10.1245/s10434-012-2326-2
PMID:22451235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3407309/
Abstract

BACKGROUND

Little is known about resource utilization (number of days in the hospital or medical care) between diagnosis and death in patients with pancreatic cancer.

METHODS

Using Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified 25,476 patients with pancreatic cancer (1992-2005). Hospital and medical care days per person-month from the time of diagnosis were described, stratified by stage, treatment, and survival duration.

RESULTS

Hospital/medical care days vary by length of survival and treatment strategy in patients with pancreatic cancer. For all stages, patients were in the hospital a mean of 6.4 days and received medical care a total of 9.0 days in the first month after diagnosis, decreasing to 1.7 and 3.7 days per month, respectively, by the end of the first year. Hospital/medical care days per month of life were higher in patients with shorter survival but increased sharply at the end of life in all patients, regardless of duration of survival. In patients with locoregional disease, resection was associated with a higher number of hospital/medical care days during the first 4 months after diagnosis, but fewer at the end of the first year. For distant disease, hospital days were similar but days in medical care were higher for patients receiving chemotherapy, increasing especially at the end of life.

CONCLUSIONS

This study is the first to quantify hospital/medical care days in patients with pancreatic cancer by stage, treatment, and survival. This information will provide realistic expectations and allow for treatment decisions based on patient preferences.

摘要

背景

关于胰腺癌患者从诊断到死亡之间的资源利用(住院天数或医疗护理天数)情况知之甚少。

方法

我们使用监测、流行病学和最终结果(SEER)-医疗保险链接数据,确定了 25476 名胰腺癌患者(1992-2005 年)。根据分期、治疗和生存时间,描述了每个人每月的住院和医疗护理天数。

结果

在胰腺癌患者中,住院/医疗护理天数因生存时间和治疗策略而异。所有分期的患者在诊断后第一个月平均住院 6.4 天,总共接受医疗护理 9.0 天,到第一年结束时,分别减少至每月 1.7 天和 3.7 天。无论生存时间长短,所有患者的生存期间每月住院/医疗护理天数都较高,但在生命末期急剧增加。对于局部区域疾病患者,手术与诊断后前 4 个月的住院/医疗护理天数较多相关,但在第一年结束时较少。对于远处疾病,住院天数相似,但接受化疗的患者的医疗护理天数较高,尤其是在生命末期。

结论

本研究首次按分期、治疗和生存时间量化了胰腺癌患者的住院/医疗护理天数。这些信息将提供现实的预期,并允许根据患者的偏好做出治疗决策。

相似文献

1
Hospital and medical care days in pancreatic cancer.胰腺癌的住院和医疗护理天数。
Ann Surg Oncol. 2012 Aug;19(8):2435-42. doi: 10.1245/s10434-012-2326-2. Epub 2012 Mar 27.
2
The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma.抑郁对胰腺腺癌诊断时分期、治疗和生存的影响。
Surgery. 2012 Sep;152(3):403-13. doi: 10.1016/j.surg.2012.06.010.
3
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.癌症患者接受不同治疗方案的总生存期估计:在监测、流行病学和最终结果(SEER)-医疗保险链接数据库中模拟假设的目标试验。
JAMA Netw Open. 2020 Mar 2;3(3):e200452. doi: 10.1001/jamanetworkopen.2020.0452.
4
Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.局部进展期胰腺腺癌患者的癌症专家咨询、治疗和结局的种族差异。
Ann Surg Oncol. 2009 Nov;16(11):2968-77. doi: 10.1245/s10434-009-0656-5. Epub 2009 Aug 11.
5
EUS and survival in patients with pancreatic cancer: a population-based study.EUS 与胰腺癌患者的生存:一项基于人群的研究。
Gastrointest Endosc. 2010 Jul;72(1):78-83, 83.e1-2. doi: 10.1016/j.gie.2010.01.072.
6
Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.老年胰腺腺癌患者的治疗轨迹和多模式治疗的应用。
Surgery. 2014 Aug;156(2):280-9. doi: 10.1016/j.surg.2014.03.001. Epub 2014 Mar 14.
7
Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma.胰腺癌的临床表型、治疗和生存趋势。
Am J Surg. 2019 Jan;217(1):103-107. doi: 10.1016/j.amjsurg.2018.05.017. Epub 2018 May 23.
8
A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.老年胰腺腺癌患者行胰腺切除术与化疗的生存结局比较分析。
Cancer. 2016 Nov 15;122(21):3378-3385. doi: 10.1002/cncr.30199. Epub 2016 Jul 15.
9
Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?评估第 8 版 AJCC 病理分期与临床分期系统在胰腺腺癌中的应用:是否需要重新审视这一传统观点?
Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):64-69. doi: 10.1016/j.hbpd.2018.01.014. Epub 2018 Jan 31.
10
Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer.社会经济变量与早期胰腺癌患者切除术、分期和生存的关联。
JAMA Surg. 2016 Apr;151(4):338-45. doi: 10.1001/jamasurg.2015.4239.

引用本文的文献

1
Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients.胰腺腺癌患者中FOLFIRINOX化疗毒性的预测因素
Future Oncol. 2025 Mar;21(6):691-697. doi: 10.1080/14796694.2025.2461442. Epub 2025 Feb 9.
2
Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer.临床数据预测模型,用于识别早期胰腺癌患者。
JCO Clin Cancer Inform. 2021 Mar;5:279-287. doi: 10.1200/CCI.20.00137.

本文引用的文献

1
End-of-life care in Medicare beneficiaries dying with pancreatic cancer.医疗保险受益人生前患有胰腺癌的临终关怀。
Cancer. 2011 Nov 1;117(21):5003-12. doi: 10.1002/cncr.26115. Epub 2011 Apr 14.
2
Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality.尽管局部区域性胰腺癌老年患者的短期发病率和死亡率较高,但切除术仍能带来获益。
J Am Geriatr Soc. 2011 Apr;59(4):647-54. doi: 10.1111/j.1532-5415.2011.03353.x. Epub 2011 Mar 31.
3
Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy.术前因素预测胰十二指肠切除术后围手术期的发病率和死亡率。
Ann Surg Oncol. 2011 Aug;18(8):2126-35. doi: 10.1245/s10434-011-1594-6. Epub 2011 Feb 20.
4
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
5
Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.验证一项预测规则以最大化早期胰腺腺癌的治愈性(R0)切除。
HPB (Oxford). 2009 Nov;11(7):606-11. doi: 10.1111/j.1477-2574.2009.00110.x.
6
Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study.可切除胰腺和壶腹周围癌辅助动脉内化疗和放疗与单纯手术治疗后生活质量的前瞻性随机对照研究。
Cancer. 2010 Feb 15;116(4):830-6. doi: 10.1002/cncr.24809.
7
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.吉西他滨对比吉西他滨联合卡培他滨治疗晚期胰腺癌的 III 期随机对照研究。
J Clin Oncol. 2009 Nov 20;27(33):5513-8. doi: 10.1200/JCO.2009.24.2446. Epub 2009 Oct 26.
8
Effect of combined treatment methods on quality of life in patients with pancreatic cancer.联合治疗方法对胰腺癌患者生活质量的影响。
Am J Ther. 2009 Jul-Aug;16(4):316-8. doi: 10.1097/MJT.0b013e318195e33c.
9
Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.纵向生活质量数据可为胰腺癌辅助治疗的影响提供见解——ESPAC-1数据的亚组分析
Int J Cancer. 2009 Jun 15;124(12):2960-5. doi: 10.1002/ijc.24270.
10
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.一项将谷胱甘肽磷酰胺与最佳支持治疗相比较的随机III期试验,该试验针对的是先前接受过吉西他滨治疗的转移性胰腺腺癌患者。
Eur J Cancer. 2009 Jun;45(9):1589-96. doi: 10.1016/j.ejca.2008.12.022. Epub 2009 Jan 31.